A Modular Multi-Arm, Phase 1, Adaptive Design Study to Evaluate the Safety and Tolerability of RXC004, Alone and in Combination With Anti-cancer Treatments, in Patients With Advanced Malignancies
Latest Information Update: 11 Jun 2024
At a glance
- Drugs Nivolumab (Primary) ; RXC 004 (Primary)
- Indications Biliary cancer; Colorectal cancer; Gastric cancer; Malignant thymoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Redx Pharma
- 05 Jul 2023 Planned End Date changed from 1 Dec 2021 to 29 Sep 2023.
- 05 Jul 2023 Planned primary completion date changed from 1 Jul 2021 to 29 Sep 2023.
- 08 Jun 2023 Status changed from recruiting to completed.